Metastasis of cancer of the rectum and sigmoid flexure

Swinton, Neil W.; Legg, Merle A.; Lewis, F. Gary

doi:10.1007/bf02630531

Cited by 29 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A summary of patterns of persistent or recurrent disease as obtained from clinical or autopsy studies of colorectal cancer patients is contained in Table 2 (2, [39][40][41][42][43][44][45][46][47]. In most of these reports the type of therapy that the patients received was not specified; many patients went untreated.…”

Section: Patterns Of Spread and Recurrence Of Colorectal Cancer Metasmentioning

confidence: 99%

See 1 more Smart Citation

Clinical perspective of human colorectal cancer metastasis

1984

View full text Add to dashboard Cite

Death from colorectal cancer frequently results from manifestations of recurrent local or metastatic disease following initial 'curative' therapy. Presently, the attempted curative treatment of recurrent colorectal cancer lays in the hands of the surgeon. This paper reviews the natural history of surgically treated large bowel cancer and summarizes published and National Cancer Institute experience with the surgical therapy of recurrent disease. A schema with rationale is offered for follow-up of the patient following 'curative' bowel resection. The treatment of recurrent disease incorporating the use of CEA initiated second-look laparotomy is advocated. Hepatic and pulmonary resections for metastatic disease are accepted as important therapeutic endeavours, and are discussed in some detail. It is concluded that of all patients diagnosed as having large bowel cancer, roughly 70% are resectable for cure at time of presentation, and 45% will indeed be cured by primary resection. Of the 25% who fail primary therapy, approximately 20% (5% of all colorectal cancer patients) can be cured by local re-resection or hepatic or pulmonary resection.

show abstract

Section: Patterns Of Spread and Recurrence Of Colorectal Cancer Metasmentioning

confidence: 99%

“…Pulmonary metastases occur at some time in approximately 20% of colorectal cancer patients (Table 2) (2,(39)(40)(41)(42)(43)(44). Two to four percent of patients undergoing curative resection of their primary tumor develop recurrences isolated to the lungs (Table 3) (50,51,56,57).…”

Section: Pulmonary Metastatic Colorectal Cancermentioning

confidence: 99%

Clinical perspective of human colorectal cancer metastasis

1984

View full text Add to dashboard Cite

show abstract

“…The liver is the most common site of metastasis from colon neoplasms and quite often is the only site of involvement. The prognosis for patients with liver involvement is poor [2,3] and over 50% of deaths from colorectal cancer will occur from and concurrently with hepatic metastases [4].…”

Section: Introductionmentioning

confidence: 99%

Hepatic artery infusion with 5‐fluorouracil and mitomycin‐c in metastatic colorectal carcinoma phase ii study

Theodórs

Bukowski

Lavery

et al. 1982

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Thirty-two patients with hepatic metastases colorectal carcinoma were treated with hepatic artery infusion (HAI) employing 5-fluorouracil (5-FU) and mitomycin-C (mito-C). Catheters were placed percutaneously via the femoral artery. Two schedules were employed: ( I ) 5-FU 1,200 mg/m2 IA (D1-4) and mito-C 8 mg/m2IA (D1 +D4); (2) 5-FU 1,200 mg/m2 IA (Dl-6) and mito-C 8 mg/m2 IA (D1 fD4).Courses were repeated every 4 weeks. Thirty patients with measurable disease were evaluable, 22 received schedule I and 8 patients schedule 11. Complete response occurred in two patients (6.7%) and partial response in 13 patients (43.3%). Five patients (16.7%) had minimal regression. The overall response rate was 66.7%. Median survival of all patients from start of treatment was 11.2 months. Median survival of responders and nonresponders was 12.4 months and 4.6 months, respectively (PcO.05). No differences in response rates, duration of response, or survival was seen between the two schedules. Drug toxicity was moderate to severe, but morbidity of HAI per se was minimal. Intermittent HA1 of 5-FU and mito-C is a well-tolerated treatment modality associated with few serious complications. The response rate, duration of response, and the survival is comparable to continuous HA1 infusion of 5-FU or floxuridine (FUDR). As given in this mdy, mito-C did not appear to provide added benefit.

show abstract

“…Carcinoma of the colorectum is a significant health problem that affects more than 100,000 Americans annually [24]. The most common cause of death in these patients is from liver metastases [26], where the mean survival of untreated patients is approximately six months [4,161. Various therapeutic regimens have been developed to control hepatic metastases, but all have had limited success.…”

Section: Introductionmentioning

confidence: 99%

Uptake of 5‐fluorouracil during isolated perfusion of the canine liver

Stone

Jabour

Wilson

et al. 1980

Journal of Surgical Oncology

View full text Add to dashboard Cite

This study describes a technique of hepatic isolated perfusion in dogs. The uptake of 14C-labeled 5 fluorouracil (5-FU) by the normal canine liver was fourfold greater when isolated perfusion was used than when peripheral intravenous administration or hepatic artery infusion were applied. Systemic leakage of 5-FU was small during, and even following, hepatic isolated perfusion. This technique, which maximizes chemotherapy delivery to the liver while minimizing systemic toxicity, may be useful in the treatment of primary and metastatic hepatic malignancies.

show abstract

Metastasis of cancer of the rectum and sigmoid flexure

Cited by 29 publications

References 4 publications

Clinical perspective of human colorectal cancer metastasis

Clinical perspective of human colorectal cancer metastasis

Hepatic artery infusion with 5‐fluorouracil and mitomycin‐c in metastatic colorectal carcinoma phase ii study

Uptake of 5‐fluorouracil during isolated perfusion of the canine liver

Contact Info

Product

Resources

About